retatrutide nonalcoholic fatty liver disease nash trial in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment retatrutide nonalcoholic fatty liver disease

A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE -/- mice

Patients on anticoagulants should maintain consistent vitamin K intake and discuss any supplement changes with their healthcare provider

Outside of his professional pursuits, he enjoys surfing, biking, and attending concerts